Swimming Against the Nucleotides
Advances in cell and gene therapy have led to a spate of novel treatments for inherited retinal disease. But with each breakthrough comes new dilemmas...
James Bainbridge |
Tomorrow’s cures for retinopathies will likely include advanced gene and cell therapies delivered by precision surgery.
Translational research often requires both scientific and clinical input – and this demands collaboration between groups with complementary skill-sets. Developing gene or cell therapies for retinal disease requires sophisticated expertise in a range of disciplines from molecular biology to microsurgery. Close collaboration was critical for the 2017 approval of a gene therapy for Leber Congenital Amaurosis (LCA), which is a form of childhood blindness that can be caused by the lack of a gene called RPE65. The contribution of our team at UCL/Moorfields was recognized last year, when the 2018 Antonio Champalimaud Vision Award was awarded to the four groups working to develop gene therapy for this condition. Working on a new therapy for an unmet clinical need is its own reward – but it’s certainly an honor to receive such recognition!
Read the full article now
Log in or register to read this article in full and gain access to The Translational Scientist’s entire content archive. It’s FREE and always will be!
Or register now - it’s free and always will be!
You will benefit from:
- Unlimited access to ALL articles
- News, interviews & opinions from leading industry experts
Or Login via Social Media
By clicking on any of the above social media links, you are agreeing to our Privacy Notice.